Bayer will acquire ophthalmic drug developer Perfuse Therapeutics for up to $2.45 billion

格隆汇2026/05/06 07:00

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

GroLink News May 6｜Bayer announced on Wednesday that it has agreed to acquire Perfuse Therapeutics, a pharmaceutical company specializing in the development of drugs for ophthalmic diseases, in a deal valued at up to $2.45 billion. Bayer stated that Perfuse's main candidate drug is an experimental therapy for treating glaucoma and diabetic retinopathy, which is currently in a mid-stage clinical trial. Bayer will pay an upfront fee of $300 million, with the remaining payments depending on the achievement of additional development, regulatory, and commercial milestones.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

The UK’s July CPI is expected to rise by 2.9% year-on-year, marking the first acceleration in four months. In addition to a jump in energy bills due to the reset of Ofgem’s price cap, an AI-driven memory chip shortage is emerging as a new driver of inflation—Apple laptops, tablets, and Xbox consoles have all announced price increases.

华尔街见闻•2026/08/16 07:46